Gastrointestinal Cancer
Firstline Nivolumab/Chemotherapy Continues To Outperform Chemotherapy Alone for Advanced Gastric/GEJ/Esophageal Cancer At 3-Year Follow-Up
January 21, 2023
Article
In an all-randomized population of patients with advanced gastric cancer, gastroesophageal junction, or esophageal adenocarcinoma, adding nivolumab to chemotherapy yielded a 21% reduction in the risk of death.
Adding Pembrolizumab to Lenvatinib Yields Similar HRQOL Scores As Lenvatinib Alone in HCC
January 20, 2023
Article
Patients with advanced hepatocellular carcinoma experienced similar health-related quality of life scores whether they received a combination of pembrolizumab and lenvatinib or lenvatinib and placebo.
Tucatinib and Trastuzumab Combination Gains FDA Approval for RAS Wild-Type HER2+ mCRC
January 19, 2023
Article
The FDA has granted accelerated approval to tucatinib and trastuzumab for RAS wild-type, HER2-positive metastatic colorectal cancer. The prescribing information includes warnings for diarrhea and hepatotoxicity.
Lutathera Prolongs PFS in Patients with Progressive Neuroendocrine Pancreatic Tumors
January 16, 2023
Article
At a median follow-up of 40 months, patients with unresectable, progressive neuroendocrine pancreatic tumors achieved an 80% progression-free survival rate with Lutathera.
ASCO Guidelines Shine Light on Treatments for Gastroesophageal Cancer
January 11, 2023
Article
The American Society of Clinical Oncology (ASCO) has released new guidelines providing recommendations for the optimal treatment of patients with advanced gastroesophageal cancer.
Hepatic Arterial Infusion Chemotherapy-Administered FOLFOX Delivers Longer DFS Rates in Hepatocellular Carcinoma
January 09, 2023
Article
Adjuvant treatment with hepatic arterial infusion chemotherapy-infused FOLFOX improved disease-free survival rates for patients with hepatocellular carcinoma with microvascular invasion.
Mitazalimab Plus mFOLFIRINOX Boosts Responses in Previously Untreated Metastatic Pancreatic Cancer
January 07, 2023
Article
A combined regimen of mitazalimab and mFOLFIRINOX resulted in a 52% objective response rate among 23 patients with metastatic pancreatic cancer.
A Look Back at 2022 FDA Approvals in Oncology
January 02, 2023
Podcast
In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.
Label Update for Capecitabine Expands and Updates Indications
December 22, 2022
Article
The FDA has approved updated labeling for capecitabine under Project Renewal, an Oncology Center of Excellence initiative aimed at updating labeling information for certain older oncology drugs.
Futibatinib Approval Ushers in Targeted Therapy Option for Patients With Unresectable, Intrahepatic FGFR2-Positive Cholangiocarcinoma
December 06, 2022
Article
Osheka Hansel, APRN, discusses the recent approval of futibatinib (Lytgobi) for patients with unresectable, locally advanced or metastatic intrahepatic FGFR2-positive cholangiocarcinoma.